Masson E - Search Results

1

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Feng Y, et al. Among authors: masson e. Clin Cancer Res. 2013 Jul 15;19(14):3977-86. doi: 10.1158/1078-0432.CCR-12-3243. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741070

2

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma.

Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Feng Y, et al. Among authors: masson e. Br J Clin Pharmacol. 2014 Jul;78(1):106-17. doi: 10.1111/bcp.12323. Br J Clin Pharmacol. 2014. PMID: 24433434 Free PMC article. Clinical Trial.

3

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD. Weber J, et al. Among authors: masson e. Cancer Immun. 2013 May 1;13:7. Print 2013. Cancer Immun. 2013. PMID: 23833564 Free PMC article. Clinical Trial.

4

Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients.

Shen J, Townsend R, You X, Shen Y, Zhan P, Zhou Z, Geng D, Wu D, McGirr N, Soucek K, Proszynski E, Pursley J, Masson E. Shen J, et al. Among authors: masson e. Clin Drug Investig. 2014 Feb;34(2):117-26. doi: 10.1007/s40261-013-0153-2. Clin Drug Investig. 2014. PMID: 24217983 Free PMC article.

5

Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.

Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E. Syed S, et al. Among authors: masson e. J Clin Pharmacol. 2012 Jun;52(6):914-21. doi: 10.1177/0091270011407495. Epub 2011 Jun 9. J Clin Pharmacol. 2012. PMID: 21659627 Clinical Trial.

6

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. Giles F, et al. Among authors: masson e. Clin Cancer Res. 2006 Aug 1;12(15):4628-35. doi: 10.1158/1078-0432.CCR-06-0511. Clin Cancer Res. 2006. PMID: 16899611 Clinical Trial.

7

Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.

Al-Huniti N, Petersson K, Tang W, Masson E, Li J. Al-Huniti N, et al. Among authors: masson e. Br J Clin Pharmacol. 2018 Apr;84(4):726-737. doi: 10.1111/bcp.13495. Epub 2018 Jan 31. Br J Clin Pharmacol. 2018. PMID: 29274100 Free PMC article.

8

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.

Kaufman HL, Schwartz LH, William WN Jr, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Kaufman HL, et al. Among authors: masson e. J Cancer Res Clin Oncol. 2018 Nov;144(11):2245-2261. doi: 10.1007/s00432-018-2738-x. Epub 2018 Aug 21. J Cancer Res Clin Oncol. 2018. PMID: 30132118 Review.

9

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.

LoRusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E. LoRusso P, et al. Among authors: masson e. Cancer Chemother Pharmacol. 2011 Dec;68(6):1377-85. doi: 10.1007/s00280-011-1603-2. Epub 2011 Apr 3. Cancer Chemother Pharmacol. 2011. PMID: 21461891 Clinical Trial.

10

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.

Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S. Yang Z, et al. Among authors: masson e. J Clin Pharmacol. 2013 Feb;53(2):217-27. doi: 10.1177/0091270012439208. J Clin Pharmacol. 2013. PMID: 23436267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

364 results

Search Page